Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2

Completed

Conditions studied: Lymphedema, Breast Cancer

In brief

To better understand the mechanisms leading to lymphedema development in breast cancer survivors, and the implications for potential innovative approaches to the screening, prevention and treatment of this condition.

Key facts

Study ID

NCT00383604

Run by

Stanford University

People needed

30

Starts

2005-07-01

Expected to finish

2012-04-01

Last updated by the study team

2013-05-30

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients enrolled in the proposed studies must be survivors of breast cancer at a time point at least 4 years following the initial surgery and radiotherapy for the disease.
• Patients must have a history of unilateral axillary lymph node dissection.
• Patients referred to, or that receive their care within the Stanford University Breast Cancer Program and the Stanford Center for Lymphatic and Venous Disorders.
• Patients will be required to have the capacity to provide informed consent.

You may not qualify if…

• Patients with other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate.
• Patients will not be enrolled if they are taking drugs that affect carbohydrate metabolism.
• Patients with recurrent breast cancer or other forms of pre-existing lymphedema will be ineligible.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.